Breaking News Instant updates and real-time market news.

ATNM

Actinium Pharmaceuticals

$0.56

0.0203 (3.76%)

, ONCE

Spark Therapeutics

$54.08

1.53 (2.91%)

04:55
02/13/18
02/13
04:55
02/13/18
04:55

Biotech Innovation Organization to hold a conference

BIO CEO & Investor Conference will be held in New York on February 12-13.

ATNM

Actinium Pharmaceuticals

$0.56

0.0203 (3.76%)

ONCE

Spark Therapeutics

$54.08

1.53 (2.91%)

AZRX

AzurRx BioPharma

$3.14

0.0301 (0.97%)

CUE

Cue Biopharma

$13.69

-0.49 (-3.46%)

OCRX

Ocera Therapeutics

$1.79

(0.00%)

PFE

Pfizer

$34.66

0.5 (1.46%)

ARNA

Arena Pharmaceuticals

$40.34

0.63 (1.59%)

XXII

22nd Century

$2.68

-0.05 (-1.83%)

BYSI

BeyondSpring

$26.24

-0.7545 (-2.79%)

AKBA

Akebia

$14.45

0.34 (2.41%)

GS

Goldman Sachs

$253.16

3.86 (1.55%)

SMMT

Summit Therapeutics

$10.80

0.2 (1.89%)

DERM

Dermira

$27.69

0.9 (3.36%)

SNY

Sanofi

$39.59

0.61 (1.56%)

BMY

Bristol-Myers

$63.16

0.46 (0.73%)

BTX

BioTime

$2.61

0.03 (1.16%)

EIGR

Eiger BioPharmaceuticals

$8.65

0.5 (6.14%)

EGLT

Egalet

$0.84

0.0225 (2.75%)

NVTA

Invitae

$6.29

0.05 (0.80%)

FOLD

Amicus

$14.81

0.085 (0.58%)

AGN

Allergan

$162.46

-0.31 (-0.19%)

JNJ

Johnson & Johnson

$130.27

0.74 (0.57%)

PSDV

pSivida

$1.04

(0.00%)

REGN

Regeneron

$342.67

6.29 (1.87%)

CNAT

Conatus

$5.02

-0.04 (-0.79%)

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 14

    Feb

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 26

    Feb

  • 05

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 13

    Mar

  • 25

    Mar

  • 04

    Apr

  • 08

    Apr

  • 02

    May

  • 30

    May

  • 30

    Jun

  • 12

    Sep

ATNM Actinium Pharmaceuticals
$0.56

0.0203 (3.76%)

12/06/17
RILY
12/06/17
INITIATION
Target $2.75
RILY
Buy
Actinium Pharmaceuticals initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Actinium Pharmaceuticals with a Buy rating and $2.75 price target. The analyst believes the company's antibody-radioisotope conjugates may change the standard of care.
09/14/17
MAXM
09/14/17
INITIATION
Target $3
MAXM
Buy
Actinium Pharmaceuticals initiated with a Buy at Maxim
Maxim analyst Jason McCarthy started Actinium Pharmaceuticals with a Buy rating and $3 price target, saying he believes the company's Iomab-B treatment could become the new standard of care in bone marrow transplants. He predicts that success in acute myeloid leukemia will lead to expansion of the use of Iomab-B to multiple other cancers.
10/23/17
ROTH
10/23/17
INITIATION
Target $6
ROTH
Buy
Actinium Pharmaceuticals resumed with a Buy at Roth Capital
Roth Capital analyst Jotin Marango resumed coverage of Actinium Pharmaceuticals with a Buy rating and $6 price target as he believes it offers discounted entry into clinical-stage AML biologics.
ONCE Spark Therapeutics
$54.08

1.53 (2.91%)

01/25/18
WEDB
01/25/18
NO CHANGE
Target $40
WEDB
Underperform
Spark Therapeutics price target raised to $40 from $35 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Spark Therapeutics (ONCE) to $40 from $35 saying that Luxturna licensing deal with Novartis (NVS) is a positive. However, the analyst believes long-term thesis remains unchanged, and reiterates an Underperform rating on Spark's shares.
02/12/18
MZHO
02/12/18
INITIATION
Target $79
MZHO
Buy
Spark Therapeutics initiated with a Buy at Mizuho
Mizuho analyst Difei Yang started Spark Therapeutics with a Buy rating and a $79 price target.
02/08/18
RBCM
02/08/18
INITIATION
Target $65
RBCM
Outperform
Spark Therapeutics assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed coverage of Spark Therapeutics (ONCE) with an Outperform rating and a price target of $65. MacKay says the FDA approval of Luxturna and "ex-Novartis (NVS) collaboration" helps to de-risk the company's earlier-stage hemophilia and inherited retinal disease assets, calling Spark Therapeutics a "trailblazer in the gene therapy space".
01/25/18
CANT
01/25/18
NO CHANGE
Target $105
CANT
Overweight
Cantor reiterates $105 target on Spark Therapeutics after Novartis deal
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on Spark Therapeutics (ONCE) with a $105 price target after the company announced a licensing and supply agreement with Novartis (NVS). The deal further emphasizes the "significant value" of Luxturna's commercial opportunity, Piros tells investors in a research note. He believes the agreement places the drug with a strong commercial partner outside the U.S. while enabling Spark to remain focused on the domestic launch and development pipeline.
AZRX AzurRx BioPharma
$3.14

0.0301 (0.97%)

07/24/17
HCWC
07/24/17
INITIATION
Target $8
HCWC
Buy
AzurRx BioPharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started AzurRx BioPharma with a Buy rating and $8 price target. The analyst believes MS1819 could become a best-in-class treatment for exocrine pancreatic insufficiency.
CUE Cue Biopharma
$13.69

-0.49 (-3.46%)

OCRX Ocera Therapeutics
$1.79

(0.00%)

11/03/17
HCWC
11/03/17
DOWNGRADE
Target $1.75
HCWC
Neutral
Ocera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded Ocera Therapeutics (OCRX) to Neutral saying he does not expect competing takeover bids to rival Mallinckrodt's (MNK). The analyst has a $1.75 price target for the shares.
11/02/17
BMOC
11/02/17
NO CHANGE
BMOC
Outperform
Mallinckrodt bolsters pipeline with 'interesting' Ocera deal, says BMO Capital
BMO Capital analyst Gary Nachman believes Mallinckrodt (MNK) is taking the right approach with a deal to buy Ocera Therapeutics (OCRX) for a "very modest" upfront plus a contingent value right. With the deal, Mallinckrodt bolsters its pipeline and reduces concentration risk for Acthar, Nachman said. The analyst, who thinks Ocera's OCR-002 could have significant potential, reiterates an Outperform rating on Mallinckrodt shares.
PFE Pfizer
$34.66

0.5 (1.46%)

02/07/18
HCWC
02/07/18
NO CHANGE
Target $31
HCWC
Buy
Achaogen price target raised to $31 from $25 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Achaogen (AKAO) to $31 after the FDA classified the outcome of its Q4 reinspection of Pfizer's (PFE) McPherson, Kansas facility as Voluntary Action Indicated. The news provides a clear regulatory path for approval of plazomicin out of the McPherson facility, Arce tells investors in a research note. He views the outcome as an "important risk-reducing development" that removes an overhang on Achaogen shares. The analyst keeps a Buy rating on the name.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
01/29/18
RHCO
01/29/18
NO CHANGE
Target $40
RHCO
Hold
Pfizer price target raised to $40 from $33 at SunTrust
SunTrust analyst John Boris raised his price target on Pfizer to $40 and kept his Hold rating ahead of this week's earnings. The analyst attributes the price outlook revision to the positive impact of the tax changes, but notes that "transformative large-scale M&A" is needed to bring about return to "robust" long-term growth.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
ARNA Arena Pharmaceuticals
$40.34

0.63 (1.59%)

01/17/18
FBCO
01/17/18
INITIATION
Target $44
FBCO
Outperform
Arena Pharmaceuticals initiated with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster started Arena Pharmaceuticals with an Outperform rating and $44 price target. The analyst sees a "catalyst-rich" 2018 for the company, starting with proof-of-concept data for etrasimod in ulcerative colitis in Q1. He also believes ralinepag in pulmonary arterial hypertension has the potential to be best-in-class.
01/17/18
LEER
01/17/18
NO CHANGE
Target $56
LEER
Outperform
Arena Pharmaceuticals price target raised to $56 on etrasimod upside at Leerink
Leerink analyst Joseph Schwartz raised his price target for Arena Pharmaceuticals to $56 from $53 saying that after a strong 2H17 due to positive Phase 2 ralinepag data in pulmonary arterial hypertension, he believes etrasimod can deliver upside in ulcerative colitis in Q1. The analyst reiterates an Outperform rating on the shares.
01/18/18
01/18/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Caterpillar (CAT) initiated with a Buy at Berenberg. 2. Rosehill Resources (ROSE) initiated with an Outperform at Northland. 3. Arena Pharmaceuticals (ARNA) initiated with an Outperform at Credit Suisse. 4. Electronic Arts (EA) was initiated with an Outperform at Bernstein, while Activision Blizzard (ATVI) was initiated with a Market Perform. 5. Brookfield Business Partners (BBU) initiated with a Sector Perform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/18
WELS
01/03/18
UPGRADE
Target $53
WELS
Outperform
Arena Pharmaceuticals upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Arena Pharmaceuticals (ARNA) to Outperform and raised his price target for the shares to $53 from $19. The stock closed yesterday up 7% to $36.21. An improved FDA environment could facilitate approval of ralinepag in pulmonary arterial hypertension, Birchenough tells investors in a research note. He's upgrading the shares ahead of the Phase 2 data for S1P modulator etrasimod in ulcerative colitis. The analyst believes recent data from Celgene's (CELG) competing S1P modulator ozanimod "lowers the bar for differentiation." Both of Arena's assets "could attract large Pharma interest," Birchenough adds.
XXII 22nd Century
$2.68

-0.05 (-1.83%)

BYSI BeyondSpring
$26.24

-0.7545 (-2.79%)

12/05/17
GHSC
12/05/17
INITIATION
Target $56
GHSC
Buy
BeyondSpring initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated BeyondSpring with a Buy and $56 price target saying its lead drug, Plinabulin, is a differentiated standard in the potential treatment option for chemotherapy-induced neutropenia (CIN). He thinks Plinabulin could also play a key role in improving results with traditional cancer drugs and immunotherapies that are limited by their significant toxicities.
07/14/17
RODM
07/14/17
NO CHANGE
Target $50
RODM
Buy
BeyondSpring price target raised to $50 from $43 at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis raised his price target for BeyondSpring to $50 after increasing his projected chance of success for neutropenia to 55% from 50%. The analyst admits, however, that upcoming data and the share lockup expiration "could make September quite volatile." Pantginis keeps a Buy rating on the shares.
10/26/17
HCWC
10/26/17
NO CHANGE
Target $60
HCWC
Buy
BeyondSpring price target raised to $60 from $50 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for BeyondSpring to $60 saying new regulatory rules in China may accelerate Plinabulin approval. The CPC Central Committee and State Council of China's new regulatory guidelines should be beneficial to BeyondSpring by accelerating approval and extending intellectual property protection, Pantginis tells investors in a research note. He keeps a Buy rating o the shares.
08/22/17
MAXM
08/22/17
INITIATION
Target $52
MAXM
Buy
BeyondSpring initiated with a Buy at Maxim
Maxim analyst Gabrielle Zhou started BeyondSpring with a Buy rating and $52 price target, stating that the company's unique small molecule to prevent chemotherapy-induced neutropenia has the potential to become the new standard of care for chemotherapy patients.
AKBA Akebia
$14.45

0.34 (2.41%)

12/07/17
12/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sogou (SOGO) initiated with an Overweight at JPMorgan. 2. Amag Pharmaceuticals (AMAG) initiated with a Neutral at B. Riley FBR. 3. Akebia (AKBA) initiated with a Buy at BTIG. 4. Synnex (SNX) initiated with a Buy at SunTrust. 5. Cancer Genetics (CGIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
PIPR
02/12/18
NO CHANGE
PIPR
Overweight
Piper still positive on Akebia following vadadustat program updates
Piper Jaffray analyst Christopher Raymond said he still has a positive outlook on Akebia after the company confirmed the timing for its pivotal INNO2VATE and PRO2TECT Phase 3 trials and made updates on its additional FO2RWARD and TRILO2GY trials. He thinks those updates can provide commercial benefit globally and management said the trial changes do not change its cash guidance, noted Raymond, who keeps an Overweight rating on Akebia shares.
12/18/17
PIPR
12/18/17
INITIATION
Target $26
PIPR
Overweight
Akebia initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond initiated Akebia (AKBA) with an Overweight rating and a price target of $26. The analyst cites the company's "combination of sound biology, clean safety, meaningful unmet medical need and an attractive relative valuation". While the near term prospects for Akebia revolve around first-to- market player Fibrogen (FGEN) in the HIF space, the analyst contends, Akebia can generate its own share of anemia market once its lead compound vadadustat is approved.
12/07/17
BTIG
12/07/17
INITIATION
Target $30
BTIG
Buy
Akebia initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Akebia with a Buy rating and a price target of $30. Hazlett says the company's development of Vadadustat - an HIF-PH inhibitor for anemia secondary to chronic kidney disease - has the potential to attain "hemoglobin control with material advantages compared to current standard-of-care injectable erythropoiesis stimulating agents". With its development partnerships in Japan and EU, the treatment is in a Phase 3 program expected for readouts in the first half of 2019.
GS Goldman Sachs
$253.16

3.86 (1.55%)

02/02/18
MSCO
02/02/18
NO CHANGE
MSCO
BofA, JPMorgan, Citi best positioned for tougher CCAR test, says Morgan Stanley
Morgan Stanley analyst Betsy Graseck said she had expected an easier stress test from the Federal Reserve but that the 2018 CCAR test actually seems tougher than last year, given the more intense recessions and lower asset prices modeled in it. A tougher test makes her less optimistic on her strong payout growth expectations, said Graseck, who sees Bank of America (BAC), JPMorgan (JPM) and Citi (C) as best positioned to "weather the storm" and increase payouts given their resilient balance sheets and significant excess capital. She sees Goldman Sachs (GS), which recently cut buybacks, as at risk from a tougher test, which likely weighs on the bank's 2018 ask, Graseck added.
01/31/18
DBAB
01/31/18
NO CHANGE
Target $15
DBAB
Sell
GE likely to be dropped from Dow 30 index, says Deutsche Bank
General Electric (GE) is likely to be dropped from the Dow Jones Industrial Average after being in the index of 30 companies for over 110 years as an original member since 1896, Deutsche Bank analyst John Inch tells investors in a research note. The chances that GE could be removed from the Dow are increasing as the company continues to face "substantial challenges," the analyst writes. These include "earnings and cash pressure, tough global power generation markets, aggressive downsizing, shrinking its portfolio, management shake-up and SEC investigations," Inch argues. He sees "headline risk" as the most significant risk factor if GE were to be dropped from the Dow, "potentially amplified by GE's high mix of retail investors." Inch notes that the last major Dow shakeup occurred in September 2003, when American Airlines (AAL), Bank of America (BAC) and Hewlett Packard (HPQ) were removed and Goldman Sachs (GS), Nike (NKE) and Verizon (VZ) were added. Inch has a Sell rating on General Electric with a $15 price target. The shares closed yesterday down 33c to $15.95.
01/25/18
WELS
01/25/18
NO CHANGE
Target $320
WELS
Outperform
Goldman Sachs price target raised to $320 from $295 at Wells Fargo
Wells Fargo analyst Mike Mayo raised his price target for Goldman Sachs to $320 form $295 saying it should have the highest pre-tax margin this decade by 2019. The analyst notes that Goldman has preserved more of its infrastructure than peer even while reducing comp and non-comp expense, which should result in greater revenues at lower marginal cost. Mayo reiterates an Outperform rating on the shares.
01/18/18
RBCM
01/18/18
NO CHANGE
Target $265
RBCM
Sector Perform
Goldman Sachs price target raised to $265 from $240 at RBC Capital
RBC Capital analyst Gerard Cassidy raised his price target on Goldman Sachs to $265 and kept his Sector Perform rating following Q4 earnings. Cassidy contends that the weak trading results, particularly in FICC, were more than offset by Goldman's "diversified revenue mix, led by strong Investment banking results and private equity gains". The analyst also notes the company's efforts to grow and deepen relationships across its major businesses, while deriving further benefits from the "actual and perceived loosening of regulations under the Trump administration".
SMMT Summit Therapeutics
$10.80

0.2 (1.89%)

01/25/18
HCWC
01/25/18
NO CHANGE
Target $75
HCWC
Buy
H.C. Wainwright sees potential competitive advantages for Sarepta
H.C. Wainwright analyst Debjit Chattopadhyay says the "steady percolation of not so good news" that delayed the initial public offering of Solid Biosciences translates into potential competitive advantages for Sarepta Therapeutics (SRPT). In addition, the analyst believes Sarepta partner Summit Therapeutics' (SMMT) preliminary analysis this morning from its ongoing Duchenne muscular dystrophy Phase 2 study provided "mixed signals." Chattopadhyay keeps a Buy rating on Sarepta with a $75 price target. The stock in afternoon trading is up 3%, or $2.17, to $67.95.
01/04/18
RHCO
01/04/18
INITIATION
Target $24
RHCO
Buy
Summit Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Summit Therapeutics (SMMT) with a Buy rating and a price target of $24. Nash says the company's ezutromid drug has the potential to address all 50K cases of Duchenne muscular dystrophy in the developed world, expecting the key interim data announced this quarter to be strong. The analyst notes that DMD remains a "high profile orphan disease", and only Sarepta's (SRPT) Exondys 51 treatment address about 13% of its patients.
01/25/18
HCWC
01/25/18
NO CHANGE
Target $16
HCWC
Buy
Summit Therapeutics data provide 'mixed signals,' says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says this morning's preliminary analysis from Summit Therapeutics' ongoing Duchenne muscular dystrophy Phase 2 study provides "mixed signals." There was a "compelling" decline in developmental myosin and an increase in mean utrophin protein, but these positive changes had limited readthrough into T2 MRI, 6MWT and NSAA, Chattopadhyay tells investors in a research note. The analyst believes that for the shares to "breakout," Summit needs to address its financing overhang and the 48-week readout needs to provide compelling evidence of disease stabilization. Chattopadhyay has a Buy rating on Summit Therapeutics with a $16 price target. The stock in late morning trading is up 24% to $15.14.
12/01/17
HCWC
12/01/17
INITIATION
Target $16
HCWC
Buy
Summit Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay assumed coverage of Summit Therapeutics with a Buy rating and $16 price target. A "compelling" readout in Q1 of 2018 for ezutromid, a potential once daily oral treatment for Duchenne Muscular Dystrophy, could send the stock "significantly higher," Chattopadhyay tells investors in a research note. If the PhaseOut tial fails to generate a compelling signal, Summit is likely to trade at cash, or $3 per share, the analyst adds.
DERM Dermira
$27.69

0.9 (3.36%)

12/05/17
GUGG
12/05/17
INITIATION
Target $30
GUGG
Buy
Dermira initiated with a Buy at Guggenheim
Guggenheim initiated Dermira with a Buy and a $30 price target.
01/17/18
LEER
01/17/18
NO CHANGE
Target $48
LEER
Outperform
Dermira price target raised to $48 from $42 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Dermira to $48 from $42 saying his deep dive analysis of the opportunity for lebrikizumab in atopic dermatitis suggests substantial upside potential. The analyst reiterates an Outperform rating on the shares.
01/16/18
CANT
01/16/18
NO CHANGE
Target $45
CANT
Overweight
Dermira should rally on two first half catalysts, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen believes two positive catalysts in the first half of 2018 should push shares of Dermira higher. Friday's rally can be attributed to short covering and buyers of the stock ahead of the topline DRM01 Phase 3 acne data, Chen tell investors in a research note. She believes the data, expected in Q1, will be positive. The next important catalyst after Phase 3 acne data is an approval for DRM04 to treat hyperhidrosis, or excessive sweating, Chen adds. She notes the FDA action data is June 30. The analyst has an Overweight rating on Dermira with a $45 price target.
11/30/17
CANT
11/30/17
NO CHANGE
Target $45
CANT
Overweight
Cantor sees 'lots of catalysts' to move Dermira shares higher
After meeting with management, Cantor Fitzgerald analyst Louise Chen says she sees "lots of catalysts" to move shares of Dermira higher in 2018. The analyst expects expect positive Phase 3 data from Dermira's olumacostat glasaretil in 2018 and thinks the market opportunity for Lebrikizumab is being underappreciated. Chen has an Overweight rating on the shares with a $45 price target.
SNY Sanofi
$39.59

0.61 (1.56%)

01/23/18
LEHM
01/23/18
DOWNGRADE
LEHM
Underweight
Sanofi downgraded to Underweight from Equal Weight at Barclays
01/24/18
ARGS
01/24/18
DOWNGRADE
ARGS
Hold
Bioverativ downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Bioverativ (BIVV) to Hold from Buy after the company announced a deal to be acquired by Sanofi (SNY) for $105 per share in cash. Hellweg says the strong run-up in the stock and the forthcoming acquisition have fully valued the stock at current levels.
02/08/18
BERN
02/08/18
NO CHANGE
Target $45
BERN
Market Perform
Sanofi price target lowered to $45 from $50 at Bernstein
Bernstein analyst Tim Anderson lowered his price target for Sanofi to $45 from $50 following a "weak" quarter. The analyst reiterates a Market Perform rating on the shares.
01/24/18
FBCO
01/24/18
NO CHANGE
Target $105
FBCO
Neutral
Bioverativ price target raised to $105 from $65 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Bioverativ (BIVV) to $105 from $65 ahead of likely closing of the Sanofi (SNY) deal. The analyst reiterates a Neutral rating on Bioverativ's shares.
BMY Bristol-Myers
$63.16

0.46 (0.73%)

02/06/18
LEER
02/06/18
NO CHANGE
Target $76
LEER
Outperform
Bristol-Myers price target raised to $76 from $71 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Bristol-Myers to $76 from $71 and increased Opdivo and Yervoy estimates following positive CM-227 PFS Topline. The analyst reiterates an Outperform rating on the shares.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $88
JEFF
Buy
Bristol-Myers makes sense as potential Nektar acquirer, says Jefferies
Jefferies analyst David Steinberg believes Bloomberg's report that Nektar Therapeutics (NKTR) is exploring strategic options is not surprising. For many years Nektar's most important assets were out licensed, but that is no longer the case, Steinberg tells investors in a research note. The company's current partner Bristol-Myers Squibb (BMY) would make sense to be on the short list of potential acquirer, the analyst adds. Steinberg keeps a Buy rating on Nektar with an $88 price target.
11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
BTX BioTime
$2.61

0.03 (1.16%)

03/30/17
RAJA
03/30/17
INITIATION
RAJA
Outperform
BioTime initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated BioTime with an Outperform rating and $6 price target.
02/02/18
LSCM
02/02/18
INITIATION
Target $8
LSCM
Buy
BioTime initiated with a Buy at Lake Street
Lake Street analyst Bruce Jackson started BioTime with a Buy rating and $8 price target. The company may appear complex given its interdependent corporate structure, but there is reward for investors who can recognize the value creation underway at both BioTime and its minority investments, Jackson tells investors in a research note.
EIGR Eiger BioPharmaceuticals
$8.65

0.5 (6.14%)

01/03/18
LTCO
01/03/18
INITIATION
Target $32
LTCO
Buy
Eiger BioPharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann started Eiger BioPharmaceuticals with a Buy rating and $32 price target.
01/16/18
PIPR
01/16/18
NO CHANGE
Target $17
PIPR
Overweight
Eiger BioPharmaceuticals price target lowered to $17 from $35 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff cut his price target for Eiger BioPharmaceuticals to $17 from $35 after the Phase II Liberty study of ubenimex in pulmonary arterial hypertension failed to meet the primary and secondary endpoints. The stock in morning trading is down 44%, or $7.09, to $8.91.The analyst removed pulmonary arterial hypertension from this model but reiterates an Overweight rating on the shares for the rest of Eiger's orphan drug pipeline. The company will meet with the FDA to discuss a registrational path for Sarasar and pegylated interferon-lambda and likely start a Phase III trial by the end of 2018, Tenthoff tells investors in a research note.
01/16/18
JEFF
01/16/18
NO CHANGE
Target $26
JEFF
Buy
Eiger selloff on failed study an overreaction, says Jefferies
Jefferies analyst Maury Raycroft views the selloff today in shares of Eiger BioPharmaceuticals as an overreaction. The analyst notes that his model did not include pulmonary arterial hypertension, which failed this morning in a Phase II trial. He viewed the Liberty study as a "promising" with high reward potential, however. Nevertheless, Raycroft sees multiple near-term catalysts to drive Eiger shares. He reiterates a Buy rating on the stock with a $26 price target.
10/19/17
10/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Baker Hughes (BHGE) initiated with a Neutral at UBS. 2. Wayfair (W) initiated with a Buy at MKM Partners. 3. TerraForm Power (TERP) reinstated with a Neutral at JPMorgan. 4. Eiger BioPharmaceuticals (EIGR) initiated with a Buy at Roth Capital. 5. Northern Dynasty (NAK) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
EGLT Egalet
$0.84

0.0225 (2.75%)

11/09/17
GABE
11/09/17
DOWNGRADE
GABE
Hold
Egalet downgraded to Hold from Buy at Gabelli
Gabelli analyst Kevin Kedra downgraded Egalet to Hold citing challenges for Arymo, potential generic competition for Sprix, and lack of near-term catalysts.
09/12/17
CANT
09/12/17
NO CHANGE
Target $7
CANT
Overweight
Investors should consider owning Egalet, says Cantor
Cantor Fitzgerald analyst Brandon Folkes saying the company's five posters at Pain Week last week reinforced the sales potential of, and need for, abuse deterent products such as Arymo ER. With three approved products and a cash runway through 2020, investors should consider owning Egalet shares, Folkes tells investors in a research note. He reiterates an Overweight rating on the shares with a $7 price target.
12/07/17
CANT
12/07/17
NO CHANGE
Target $7
CANT
Overweight
Egalet cash runway through 2020 remains intact, says Cantor Fitzgerald
In a research note titled "You Win Some, You Lose Some; Cash Runway Through 2020 Remains Intact," Cantor Fitzgerald analyst Brandon Folkes says news of CVS (CVS) removing Sprix from its 2018 formulary is a negative for Egalet (EGLT). The development offsets the positive news announced last month that Apotex will not be launching an authorized generic of Sprix in March 2018, Folkes tells investors. He believes, however, that Egalet's cash runway through 2020 remains, even if Sprix revenues in 2018 are reduced by 50%. The analyst thinks Arymo ER is the primary driver of valuation for Egalet. He keeps an Overweight rating on the shares with a $7 price target.
01/03/18
STFL
01/03/18
DOWNGRADE
Target $1.5
STFL
Hold
Egalet downgraded to Hold from Buy at Stifel
Stifel analyst Annabel Samimy downgraded Egalet (EGLT) to Hold from Buy citing the difficult opioid prescribing environment, slow prescription uptake of Arymo ER and headwind from CVS/Caremark's (CVS) formulary exclusion of Sprix. Samimy lowered his price target on Egalet shares to $1.50 from $6.00.
NVTA Invitae
$6.29

0.05 (0.80%)

01/05/18
LTCO
01/05/18
INITIATION
Target $15
LTCO
Buy
Invitae initiated with a Buy at Ladenburg
Ladenburg initiated Invitae with a Buy and $15 price target.
05/08/17
05/08/17
NO CHANGE

Invitae reports Q1 EPS (64c), consensus (66c)
Reports Q1 revenue $10.3M, consensus $10.9M.
08/02/17
AGIS
08/02/17
NO CHANGE
Target $8.33
AGIS
Buy
CombiMatrix deal confusion presents arbitrage opportunity, says Aegis
Aegis analyst Benjamin Haynor noted that SEC filings related to the agreement for CombiMatrix (CBMX) to be acquired by Invitae (NVTA) present two formulas for the calculation of the exchange ratio, which he believes is causing some confusion, creating an arbitrage opportunity. He reiterates his Buy rating on CombiMatrix and raised his price target on the stock to $8.33 from $8.10, adding that the post-announcement rise in Invitae shares may make his target conservative if that move up holds.
08/04/17
LTCO
08/04/17
DOWNGRADE
LTCO
Neutral
CombiMatrix downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin Degeeter downgraded CombiMatrix (CBMX) to Neutral citing the takeover by Invitae (NVTA).
FOLD Amicus
$14.81

0.085 (0.58%)

10/04/17
BOFA
10/04/17
NO CHANGE
Target $20
BOFA
Buy
Amicus price target raised to $20 from $15 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised Amicus' price target to $20 from $15 saying the Phase 1/2 trial results of ATB200/AT2221 in Pompe disease were impressive. The analyst thinks the strong data justifies progression into pivotal trials and may result in an accelerated approval path. Ahmad rates Amicus a Buy.
09/14/17
BARD
09/14/17
NO CHANGE
Target $16
BARD
Outperform
Amicus SD-101 failure disappointing, but removes key overhang, says Baird
Baird analyst Michael Ulz noted Amicus reported its SD-101 Phase 3 study missed all of its endpoints. Although disappointing, the trial was given a low probability of success. This news removes a key overhang for the company, setting up additional upside with its Pompe program, Ulz tells investors. He remains encouraged by the early data from the Pompe program, which should be releasing full six-month data later this month. Ulz reiterated his Outperform rating and raised his price target to $16 from $15 on Amicus shares.
09/15/17
JPMS
09/15/17
NO CHANGE
Target $15
JPMS
Overweight
JPMorgan continues to see upside in Amicus shares
JPMorgan analyst Anupam Rama says Amicus Therapeutics remains one of his top picks, and that he continues to see upside from current share levels, ahead of the upcoming Pompe data readout. The analyst sees a high probability that the Q3 data update will meet or exceed the efficacy benchmarks, leading to increased probability of success/revenue estimates across Street models. His base case, with a 75% probability of success assumption, still provides for 10%-15% upside from current share levels. His "homerun scenario," which is maintaining the 6MWD benefit shown in Q2 or better, has the stock rallying 35%-40%.
08/17/17
JPMS
08/17/17
NO CHANGE
JPMS
JPMorgan lists top SMID Biotechnology picks following Q2 results
Analysts at JPMorgan continue think selectively remains important in the small-to-mid cap Biotechnology space. The analysts listed their favorite ideas in "five key buckets." Amicus (FOLD) is the top long-term pick, Ironwood (IRWD) is the top pick among relative underperformers, Otonomy (OTIC) is the top play for a clinical/binary event, Sarepta (SRPT) is the name to take advantage of the recent share weakness, and Ignyta (RXDX) is the "underfollowed/undervalued" favorite, according to JPMorgan's Biotech team.
AGN Allergan
$162.46

-0.31 (-0.19%)

02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.
01/29/18
LEHM
01/29/18
UPGRADE
Target $230
LEHM
Overweight
Allergan upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Allergan to Overweight and raised his price target for the shares to $230 from $220. The Botox maker closed Friday down 19c to $186.93. Allergan's aesthetics franchise is undervalued at current share levels, Tsao tells investors in a research note. The analyst notes he's been on the sidelines with respect to the stock for three-plus years. Tsao says his firm's survey of 61 plastic surgeons and dermatologists validates Botox's market leader position. Physicians in the survey reported that 67% of Botox patients are "very satisfied" with results, which was well ahead of Dysport and Xeomin at 36% & 20%, respectively, Tsao writes.
01/29/18
01/29/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Allergan (AGN) upgraded to Overweight from Equal Weight at Barclays with analyst Douglas Tsao saying Allergan's aesthetics franchise is undervalued at current share levels. 2. Halliburton (HAL) upgraded to Neutral from Underweight at Atlantic Equities. 3. Ruth's Hospitality (RUTH) upgraded to Outperform from Market Perform at Raymond James with analyst Brian Vaccaro saying he is optimistic the high end steakhouse category can sustain into 2018 as strong business sentiment and corporate tax cuts bode well for T&E budgets. 4. Unilever (UN, UL) upgraded to Buy from Hold at Investec. 5. Kinder Morgan (KMI) upgraded to Buy from Hold at Argus with analyst Bill Selesky citing the company's "strong recent operational performance," the management's plan for a dividend hike, and attractive valuation in his rating change. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/18
BTIG
01/25/18
NO CHANGE
Target $7
BTIG
Buy
Synergy funding worries may be overdone, says BTIG
BTIG analyst Timothy Chiang noted that Synergy Pharmaceuticals (SGYP) announced that Trulance received expanded FDA approval for IBS-C, which puts it more on par with market leader Linzess from Ironwood (IRWD) and Allergan (AGN). He sees Trulance benefiting from increased payor access and believes the company will have sufficient cash in order to gain access to a second loan tranche of $100M expected by next month, stating that funding worries may be overdone. Chiang keeps a Buy rating and $7 price target on Synergy shares.
JNJ Johnson & Johnson
$130.27

0.74 (0.57%)

02/06/18
WELS
02/06/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson talc litigation concerns appear overblown, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen says Johnson & Johnson shares were down partly due to concerns about ongoing litigation over allegations that its talcum power products are unsafe for use because they contain asbestos which can cause mesothelioma. Based on prior high-profile product liability cases in the drug and device sectors, the analyst believes any potential settlement would be manageable for Johnson & Johnson. He reiterates an Outperform rating and $160 price target on the shares.
01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PSDV pSivida
$1.04

(0.00%)

06/13/17
LTCO
06/13/17
NO CHANGE
Target $12.5
LTCO
Buy
pSivida data on Durasert provide basis for NDA filing, says Ladenburg
Ladenburg analyst Matthew Kaplan was "impressed" with the results from pSivida's second Phase 3 trial of Durasert, which he said strongly confirm the efficacy and safety seen in the earlier study and can serve as the basis for a U.S. NDA filing. The company currently plans an NDA filing by Q4 and plans to commercialize Durasert via a contract sales organization, noted Kaplan, who reiterates a Buy rating and $12.50 price target on the stock, which is down 32c, or 15%, to $1.76 in afternoon trading.
12/04/17
RILY
12/04/17
INITIATION
Target $5
RILY
Buy
pSivida resumed with a Buy at B. Riley FBR
B. Riley FBR resumed coverage of pSivida with a Buy rating and $5 price target.
05/30/17
RODM
05/30/17
INITIATION
Target $8
RODM
Buy
pSivida initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju started pSivida with a Buy rating and $8 price target.
REGN Regeneron
$342.67

6.29 (1.87%)

02/09/18
BMOC
02/09/18
NO CHANGE
Target $398
BMOC
Market Perform
Regeneron price target lowered to $398 from $444 at BMO Capital
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron to $398 and kept his Market Perform rating after the company's Q4 results. The analyst notes that while it was a "good quarter" with encouraging Eylea outperformance and Dupixent prescriptions, he is concerned about increased Dupixent access restrictions and the lack of use in less severe patients pressuring the company's forecasts. Luchini also cites the long term risk of an increasingly competitive VEGF market.
02/09/18
02/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Sector Perform from Underperform at RBC Capital with analyst Mark Mahaney saying the fourth quarter revenue and EBITDA were materially better than expected, and while MAU's were below consensus, DAU's grew for the first time at a double-digit rate. 2. iRobot (IRBT) upgraded to Outperform from Market Perform at Raymond James with analyst Mark Strouse saying he sees a more balanced risk/reward following the recent pullback in the shares. 3. Regeneron (REGN) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney noting its selloff since last year and believes its valuation has reached a point where the selloff is overdone. 4. Teva (TEVA) upgraded to Sector Perform from Underperform at RBC Capital with analyst Randall Stanicky saying the 11% sell-off in the stock price following the company's guidance update has removed the debate around 2018 EBITDA target and sees limited downside from the current levels. 5. United Technologies (UTX) upgraded to Buy from Hold at Argus with analyst John Eade saying the company remains a leader in a number of global industries and should continue to benefit from population growth and middle class expansion in developing markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
LEER
02/12/18
NO CHANGE
Target $502
LEER
Outperform
Data from Regeneron Eylea competitors should lift some overhang, says Leerink
Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.
02/11/18
PIPR
02/11/18
NO CHANGE
Target $494
PIPR
Overweight
Piper Jaffray remains a buyer of Regeneron after Roche data
Piper Jaffray analyst Christopher Raymond remains a buyer of Regeneron (REGN) shares after Phase 2 data from Roche's (RHHBY) VEGF/Ang2 bispecific RG7716 in diabetic macular edema. While RG7716 demonstrated stag-sig BCVA gains compared to Lucentis at week 24 in DME patients previously untreated with anti-VEGF therapies, key questions on safety and efficacy remain unanswered, he contends. Given this, the analyst thinks Regeneron's Eylea remains well-positioned in the DME space. Raymond reiterates an Overweight rating and $494 price target on Regeneron's shares.
CNAT Conatus
$5.02

-0.04 (-0.79%)

02/08/18
ROTH
02/08/18
INITIATION
Target $20
ROTH
Buy
Conatus initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started Conatus with a Buy rating and $20 price target as she sees multiple shots on goal, with eyes immediately on POLT results in Q2.
10/06/17
GHSC
10/06/17
INITIATION
Target $16
GHSC
Buy
Conatus initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Conatus with a Buy and $16 price target.
04/21/17
ROTH
04/21/17
NO CHANGE
Target $12
ROTH
Buy
Conatus price target raised to $12 from $4 at Roth Capital
Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.

TODAY'S FREE FLY STORIES

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

, PCG

PG&E

$42.98

2.44 (6.02%)

18:17
06/22/18
06/22
18:17
06/22/18
18:17
Hot Stocks
Northwest Natural to sell Gill Ranch Storage to SENSA Holdings »

NW Natural (NWN)…

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

PCG

PG&E

$42.98

2.44 (6.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ORLY

O'Reilly Automotive

$285.90

-1.18 (-0.41%)

18:03
06/22/18
06/22
18:03
06/22/18
18:03
Hot Stocks
O'Reilly Automotive's O'Reilly sells 19,250 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$33.15

0.02 (0.06%)

17:46
06/22/18
06/22
17:46
06/22/18
17:46
Hot Stocks
South Jersey Industries announces approval of Elizabethtown Gas purchase »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAAS

AquaVenture

$15.36

0.12 (0.79%)

17:27
06/22/18
06/22
17:27
06/22/18
17:27
Hot Stocks
AquaVenture extends long-stop date for Ghana plant acquisition to September 30 »

AquaVenture announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Periodicals
Nissan chooses Thailand for hybrid's first export market, Nikkei reports »

Nissan has planned to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.81

-0.0068 (-0.83%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Hot Stocks
Trovagene CEO William Welch resigns, Dr. Thomas Adams named interim CEO »

Trovagene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$3.26

0.005 (0.15%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.49

-0.15 (-0.45%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Hot Stocks
Aecom to compete for $148.5M U.S. Army contract »

AECOM-Baker JV, Bryan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:17
06/22/18
06/22
17:17
06/22/18
17:17
Hot Stocks
Lockheed Martin awarded $175.3M U.S. Navy contract modification »

Lockheed Martin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:16
06/22/18
06/22
17:16
06/22/18
17:16
Hot Stocks
Lockheed Martin awarded $1.12B U.S. Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

, XLU

Utilities SPDR

$50.75

0.36 (0.71%)

17:14
06/22/18
06/22
17:14
06/22/18
17:14
General news
Week ending ETF Scorecard: Utilities and Real Estate advance, Industrials slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

XLU

Utilities SPDR

$50.75

0.36 (0.71%)

IYR

DJ US Real Estate Index Fund

$80.69

0.56 (0.70%)

XLP

Consumer Staples Sector SPDR

$51.62

0.42 (0.82%)

XLY

Consumer Discretionary Sector SPDR

$111.34

-0.15 (-0.13%)

XLB

S&P Select Materials SPDR

$58.49

0.79 (1.37%)

XLF

Financial Select Sector

$27.07

-0.145 (-0.53%)

XLV

Health Care Select Sector SPDR

$84.91

0.35 (0.41%)

XLK

Technology Select Sector SPDR

$70.78

-0.24 (-0.34%)

XLI

Industrial Select Sector SPDR

$72.59

0.22 (0.30%)

GLD

SPDR Gold Trust

$120.33

0.27 (0.22%)

SLV

iShares Silver Trust

$15.49

0.135 (0.88%)

USO

United States Oil Fund

$14.02

0.71 (5.33%)

UNG

United States Natural Gas Fund

$23.87

-0.24 (-1.00%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.91

-0.015 (-0.02%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$113.99

0.105 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.57

0.06 (0.05%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.11

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.30

0.005 (0.01%)

IWD

iShares Russell 1000 Value

$122.51

0.56 (0.46%)

IWF

iShares Russell 1000 Growth

$146.24

-0.2 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$5.43

0.14 (2.65%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Hot Stocks
Pfenex set to join Russell 2000 Index »

Pfenex announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXE

Bellatrix Exploration

$1.00

-0.0101 (-1.00%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Syndicate
Breaking Syndicate news story on Bellatrix Exploration »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$44.24

0.25 (0.57%)

16:56
06/22/18
06/22
16:56
06/22/18
16:56
Initiation
Logitech initiated  »

Logitech initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.35

0.925 (3.14%)

16:51
06/22/18
06/22
16:51
06/22/18
16:51
Hot Stocks
Breaking Hot Stocks news story on PagSeguro Digital »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

APLS

Apellis

$21.75

-0.2 (-0.91%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Conference/Events
Apellis to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Periodicals
SEC investigates whether companies rounded up earnings, WSJ reports »

The U.S. Securites and…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THRM

Gentherm

$38.20

-0.75 (-1.93%)

16:45
06/22/18
06/22
16:45
06/22/18
16:45
Conference/Events
Gentherm to hold a strategic update »

Strategic Update for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTX

MeiraGTx

$11.86

-0.97 (-7.56%)

16:43
06/22/18
06/22
16:43
06/22/18
16:43
Hot Stocks
Breaking Hot Stocks news story on MeiraGTx »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.80

0.51 (0.59%)

16:39
06/22/18
06/22
16:39
06/22/18
16:39
Conference/Events
Medtronic to hold an analyst and investor briefing »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

, FOX

21st Century Fox

$48.28

0.31 (0.65%)

16:35
06/22/18
06/22
16:35
06/22/18
16:35
Hot Stocks
21st Century Fox extends CFO John Nallen's employment contract to 2021 »

On June 22, 21st Century…

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

FOX

21st Century Fox

$48.28

0.31 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$10.97

0.5 (4.78%)

16:34
06/22/18
06/22
16:34
06/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Fennec »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBBP

Strongbridge Biopharma

$6.20

-0.15 (-2.36%)

16:33
06/22/18
06/22
16:33
06/22/18
16:33
Hot Stocks
Breaking Hot Stocks news story on Strongbridge Biopharma »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

16:30
06/22/18
06/22
16:30
06/22/18
16:30
Options
Preliminary option volume of 16.8M today »

Preliminary option volume…

COOL

PolarityTE

$38.91

-0.09 (-0.23%)

16:28
06/22/18
06/22
16:28
06/22/18
16:28
Conference/Events
PolarityTE to hold a meeting »

Management hosts a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.